RMD Quote, Financials, Valuation and Earnings

Becton Dickinson & has a net margin of 26.88% compared to ResMed's net margin of 5.86%. ResMed's return on equity of 25.56% beat Becton Dickinson &'s return on equity of 6.75%.

ResMed has a consensus price target of $267.15, signalling upside risk potential of 24.85%. On the other hand Becton Dickinson & has an analysts' consensus of $275.03 which suggests that it could grow by 33.7%. Given that Becton Dickinson & has higher upside potential than ResMed, analysts believe Becton Dickinson & is more attractive than ResMed.

ResMed has a beta of 0.755, which suggesting that the stock is 24.514% less volatile than S&P 500. In comparison Becton Dickinson & has a beta of 0.349, suggesting its less volatile than the S&P 500 by 65.131%.

ResMed has a quarterly dividend of $0.53 per share corresponding to a yield of 0.97%. Becton Dickinson & offers a yield of 1.94% to investors and pays a quarterly dividend of $1.04 per share. ResMed pays 27.65% of its earnings as a dividend. Becton Dickinson & pays out 64.52% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

ResMed quarterly revenues are $1.3B, which are smaller than Becton Dickinson & quarterly revenues of $5.2B. ResMed's net income of $344.6M is higher than Becton Dickinson &'s net income of $303M. Notably, ResMed's price-to-earnings ratio is 25.26x while Becton Dickinson &'s PE ratio is 34.17x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ResMed is 6.41x versus 2.90x for Becton Dickinson &. Usually stocks with elevated PS ratios are considered overvalued.

Bio-Rad Laboratories has a net margin of 26.88% compared to ResMed's net margin of -107.24%. ResMed's return on equity of 25.56% beat Bio-Rad Laboratories's return on equity of -23.87%.

ResMed has a consensus price target of $267.15, signalling upside risk potential of 24.85%. On the other hand Bio-Rad Laboratories has an analysts' consensus of $361.50 which suggests that it could grow by 44.82%. Given that Bio-Rad Laboratories has higher upside potential than ResMed, analysts believe Bio-Rad Laboratories is more attractive than ResMed.

ResMed has a beta of 0.755, which suggesting that the stock is 24.514% less volatile than S&P 500. In comparison Bio-Rad Laboratories has a beta of 1.119, suggesting its more volatile than the S&P 500 by 11.924%.

ResMed has a quarterly dividend of $0.53 per share corresponding to a yield of 0.97%. Bio-Rad Laboratories offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ResMed pays 27.65% of its earnings as a dividend. Bio-Rad Laboratories pays out -- of its earnings as a dividend. ResMed's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

ResMed quarterly revenues are $1.3B, which are larger than Bio-Rad Laboratories quarterly revenues of $667.5M. ResMed's net income of $344.6M is higher than Bio-Rad Laboratories's net income of -$715.8M. Notably, ResMed's price-to-earnings ratio is 25.26x while Bio-Rad Laboratories's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ResMed is 6.41x versus 2.75x for Bio-Rad Laboratories. Usually stocks with elevated PS ratios are considered overvalued.

Boston Scientific has a net margin of 26.88% compared to ResMed's net margin of 12.41%. ResMed's return on equity of 25.56% beat Boston Scientific's return on equity of 8.96%.

ResMed has a consensus price target of $267.15, signalling upside risk potential of 24.85%. On the other hand Boston Scientific has an analysts' consensus of $115.00 which suggests that it could grow by 21.99%. Given that ResMed has higher upside potential than Boston Scientific, analysts believe ResMed is more attractive than Boston Scientific.

ResMed has a beta of 0.755, which suggesting that the stock is 24.514% less volatile than S&P 500. In comparison Boston Scientific has a beta of 0.728, suggesting its less volatile than the S&P 500 by 27.188%.

ResMed has a quarterly dividend of $0.53 per share corresponding to a yield of 0.97%. Boston Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ResMed pays 27.65% of its earnings as a dividend. Boston Scientific pays out -- of its earnings as a dividend. ResMed's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

ResMed quarterly revenues are $1.3B, which are smaller than Boston Scientific quarterly revenues of $4.6B. ResMed's net income of $344.6M is lower than Boston Scientific's net income of $566M. Notably, ResMed's price-to-earnings ratio is 25.26x while Boston Scientific's PE ratio is 75.42x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ResMed is 6.41x versus 8.36x for Boston Scientific. Usually stocks with elevated PS ratios are considered overvalued.

Insulet has a net margin of 26.88% compared to ResMed's net margin of 16.85%. ResMed's return on equity of 25.56% beat Insulet's return on equity of 43.11%.

ResMed has a consensus price target of $267.15, signalling upside risk potential of 24.85%. On the other hand Insulet has an analysts' consensus of $312.92 which suggests that it could grow by 23.2%. Given that ResMed has higher upside potential than Insulet, analysts believe ResMed is more attractive than Insulet.

ResMed has a beta of 0.755, which suggesting that the stock is 24.514% less volatile than S&P 500. In comparison Insulet has a beta of 1.300, suggesting its more volatile than the S&P 500 by 30.008%.

ResMed has a quarterly dividend of $0.53 per share corresponding to a yield of 0.97%. Insulet offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ResMed pays 27.65% of its earnings as a dividend. Insulet pays out -- of its earnings as a dividend. ResMed's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

ResMed quarterly revenues are $1.3B, which are larger than Insulet quarterly revenues of $597.5M. ResMed's net income of $344.6M is higher than Insulet's net income of $100.7M. Notably, ResMed's price-to-earnings ratio is 25.26x while Insulet's PE ratio is 43.87x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ResMed is 6.41x versus 9.06x for Insulet. Usually stocks with elevated PS ratios are considered overvalued.